Method for preparing high-purity and high-stability protein
Patent Information
- Application Number
- MYPI2025001718
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-24
- Filing Date
- 2023-08-28
- Publication Date
- 2024-04-24
AI Technical Summary
It is difficult to effectively remove charge heterogeneity, mismatching and post-modification structures in recombinant human albumin due to fermentation and purification processes with existing technology, leading to protein instability and immunotoxicity problems.
Add medium and long-chain fatty acids and fatty acid salts as ligands before ion exchange chromatography, remove charge heterogeneity through anion or cation chromatography, selectively retain the correct structure of albumin, and achieve high purity and high stability of proteins. preparation.
Through this method, truncation, mismatching and modified structures in recombinant albumin can be effectively removed, the stability and purity of the protein can be improved, side effects on the human body can be reduced, and stability requirements for clinical applications can be met.
Smart Images

Figure PI2025001718_DRAWING_001 
Figure PI2025001718_DRAWING_002 
Figure PI2025001718_DRAWING_003
Abstract
Description
A method for preparing high-purity and high-stability protein Technical Field
[0001] The present invention is a method for obtaining high-purity recombinant human albumin by adding medium- and long-chain fatty acid ligands and removing charge heterogeneity through anion and / or cation chromatography. Background Art
[0002] The main pharmacological effects of human albumin include: regulating the dynamic balance of water between tissues and blood vessels, maintaining normal and constant plasma volume; at the same time, it has a high affinity for certain ions and compounds, and reversibly binds to these substances to exert a transport function; human albumin also provides the body with a large amount of amino acid reserves.
[0003] Due to these effects, human albumin can be applied across various clinical disciplines, exerting a variety of therapeutic effects. Human albumin is primarily used clinically to regulate plasma colloid osmotic pressure, expand blood volume, and treat traumatic and hemorrhagic shock, severe burns, and hypoproteinemia. It also has extensive applications in common diseases such as stroke, cirrhosis, ascites, and kidney disease. Beyond its direct clinical application, albumin has also found widespread application in culture media used in vaccine production, pharmaceutical excipients, diagnostic reagents, novel long-acting oncology formulations, cosmetics, and laboratory biological reagents.
[0004] Human albumin is a single-chain, non-glycosylated protein with a heart-shaped structure consisting of 585 amino acids, 17 pairs of disulfide bonds, one free sulfhydryl group, and a molecular weight of 66,438 daltons. Human albumin has a half-life of 19 to 21 days in the human body. The heart-shaped structure of human albumin consists of three main domains and six subdomains bounded by 17 disulfide bonds, loosely held together by van der Waals forces. Its crystal structure reveals that the disulfide bridges impart rigidity to the helical globular structure while providing sufficient flexibility to enable conformational changes in response to changes in the surrounding medium.
[0005] The conventional production method of human albumin is to extract, separate and purify it from human serum, which is collectively referred to as human serum albumin. Human albumin derived from human blood is subject to the quantity limitation of plasma sources, viral contamination of plasma donors, and individual differences in antibodies and proteins, which will pose a greater risk in clinical use. Therefore, in many countries, the instructions for use of human albumin include a viral safety statement, for example: "Standard measures taken to prevent infection caused by the use of human blood or plasma products include blood donor selection, screening of single blood donations or screening of plasma pools for special infection markers, and the use of effective production steps to inactivate / remove viruses. Even so, when using medicinal products prepared from blood or plasma, the possibility of infection by infectious pathogens cannot be ruled out. This includes unknown or emerging viruses and other pathogens." Therefore, the use of genetic recombination is the best way to effectively obtain albumin without virus contamination.
[0006] At present, the most commonly used method for expressing human albumin by genetically recombinant microorganisms that can achieve large-scale production is mainly the yeast expression system, among which Saccharomyces cerevisiae and Pichia pastoris are the most mature. However, since human albumin is a large-volume injection, the dose of each injection can reach 5 grams to 30 grams. Therefore, it is necessary to require that the total host protein residue and contaminants in the production process for each injection dose must not exceed 1ng / ml (200mg / ml-rHA). Regardless of the method used to produce recombinant human albumin, the recombinant albumin modified by glycosylation, oxidation, polymerization, mispairing and aggregation may produce immunotoxicity to the human body and may also have a certain impact on the stability of the protein. Therefore, an efficient and specific purification method is a key process element for obtaining high-purity, homogenized and uniform recombinant human albumin.
[0007] Patent WO1966 / 037515 (CN 1198844C) discloses a method for adding medium- and short-chain fatty acids, such as sodium octanoate, before ion exchange chromatography. This method can remove glycosylated and heterogeneous albumin to a certain extent. However, sodium octanoate has a weak ligand capacity and is not very effective in removing mismatched, oxidized, and truncated albumin heterogeneity.
[0008] Patent CN2019108743433 discloses a method for adding medium- and long-chain fatty acids or salts and trace amounts of polymer excipients to recombinant albumin preparations to improve the stability of the albumin preparation and prevent agglomeration and aggregation. However, this method cannot selectively remove hydrophobic heterogeneity and charge heterogeneity, defective, isomerized, or post-modified albumin, and cannot remove unstable, small amounts of heterogeneous albumin at the source.
[0009] The present invention adds a certain amount of medium- and long-chain fatty acids and fatty acid salts before refined ion exchange chromatography to meet the reasonable ligand ratio of albumin, thereby assisting the effective spatial folding of albumin to show charge heterogeneous albumin charge heterogeneous space. Under this condition, ion exchange chromatography can be used to effectively remove fragments and mismatches generated during fermentation and purification of recombinant albumin, as well as albumin with incorrect or post-modified structures.
[0010] In this specification, the term "recombinant human albumin" may also be referred to as "recombinant albumin" and / or "recombinant human serum albumin" and / or "recombinant human serum albumin" and / or "rHA" and / or "rHSA." The term "human serum albumin" refers to human albumin extracted from human serum and may also be referred to as "human serum albumin" and / or "HSA" and / or "HA" and / or "pdHSA." In this specification, the term "medium-chain fatty acids" refers to naturally occurring fatty acids with a carbon chain length greater than 10 and their salts.
[0011] Summary of the Invention
[0012] Purpose of the invention: To provide a more effective method for preparing high-purity and high-stability proteins. For specific purposes, see the multiple substantial technical effects in the specific implementation section.
[0013] In order to achieve the above purpose, the present invention adopts the following technical solutions:
[0014] A method for preparing a high-purity and high-stability protein, characterized in that:
[0015] The following steps are included:
[0016] Step A: The recombinant human albumin sample collected by the previous purification was replaced with an 80 mM PB pH 7.5 buffer system using a Millipore 10 kDa membrane. The sample collection solution was added to a mixture of a fatty acid mixture and poloxamer; the molar ratio of oleic acid, myristic acid, sodium palmitate, sodium stearate, and recombinant human albumin was 0.3:0.3:0.3:0.5:1;
[0017] After loading the sample, the anion exchange chromatography column was rinsed with purified water until neutral. The column was packed to a height of 380 mm. The column adsorbed with the sample was eluted with a 50 mM PB pH 6.5 eluent system to collect the recombinant human albumin fraction.
[0018] Step B: Cation exchange chromatography: The column was equilibrated with a 40 mM HAc-NaOH equilibrium solution system to collect the recombinant human albumin fractions; a Millipore 10 KDa flat membrane was used for desalting and replacing the solution with the cation exchange chromatography equilibrium solution system, followed by sample loading and chromatographic separation to collect the recombinant human albumin fractions.
[0019] A method for preparing a high-purity and high-stability protein, characterized in that:
[0020] The following steps are included:
[0021] Step C: The recombinant human albumin sample collected through the previous purification was replaced with a 40 mM HAc-NaOH equilibration buffer using a Millipore 10 KDa membrane pack. The cation exchange chromatography column was equilibrated with the equilibration buffer. A mixture of a fatty acid mixture and poloxamer was added to the sample; the molar ratio of oleic acid, myristic acid, sodium palmitate, sodium stearate, and recombinant human albumin was 0.3:0.3:0.3:0.5:1. Then, the recombinant human albumin components were separated by sample loading chromatography.
[0022] Step D: The recombinant human albumin fraction collected in the above step C was replaced with the buffer system of step A using a Millipore 10KDa membrane package, and the anion exchange chromatography column was equilibrated with the equilibration solution of step A. The same method was used for sample loading and purification in step A to collect the recombinant human albumin fraction.
[0023] A further technical solution of the present invention is that after step B and / or step D, the following operation is further included: when the above-mentioned chromatography is finally completed, a 100KDa and / or 30KDa and / or 10KDa membrane package is used to intercept large molecular aggregates and remove small molecular substances, and then replace and concentrate the recombinant human albumin into a stock solution with a concentration greater than 20%.
[0024] A further technical solution of the present invention is that the cation exchange medium includes but is not limited to SP strong cation or CM weak cation exchange medium, and the cation exchange medium may be selected from but is not limited to Uni-SP / CM series, UniGel-SP / CM series, NanoGel-SP series, Nano-SP series, Monomix-HC SP series, Monomix-MC SP series, GE's Sepharose series or Bestarose series of Boglong Biotechnology Co., Ltd.; the anion exchange medium includes but is not limited to Q strong anion or DEAE weak anion exchange medium, and the anion exchange medium may be selected from but is not limited to Uni-DEAE / Q series, UniGel-DEAE / Q series, NanoGel-Q series, Nano-Q series, Monomix-HC DEAE / Q series, Monomix-MC DEAE / Q series, GE's Sepharose series or Bestarose series of Boglong Biotechnology Co., Ltd.
[0025] A further technical solution of the present invention is that the weight ratio of poloxamer to recombinant albumin is 10-500 micrograms of poloxamer per gram of recombinant albumin; and poloxamer is used to promote the dissolution of fatty acids.
[0026] A further technical solution of the present invention is that the anion exchange chromatography is purified by forward elution, wherein the pH of the equilibration solution and the eluent are both between 6.0 and 9.5, and the conductivity under the conditions of the anion exchange chromatography is not higher than 20 ms / cm; or the anion exchange chromatography is purified by reverse elution, wherein the pH of the equilibration solution is between 4.0 and 6.0, and the equilibrium conductivity under the conditions of the anion exchange chromatography is not higher than 10 ms / cm.
[0027] A further technical solution of the present invention is that the anion exchange chromatography is purified by forward elution, and the pH of the equilibrium solution and the eluent are preferably between 6.5 and 9.0; the conductivity under the conditions of the anion exchange chromatography is preferably not higher than 15 ms / cm; the anion exchange chromatography is purified by reverse elution, and the pH of the equilibrium solution is preferably between 4.0 and 5.5, and the equilibrium conductivity under the conditions of the anion exchange chromatography is preferably not higher than 6 ms / cm.
[0028] A further technical solution of the present invention is that the pH of the equilibrium solution in the cation exchange chromatography condition is between 4.0 and 6.5; and the conductivity in the cation exchange chromatography condition is not higher than 10 ms / cm.
[0029] A further technical solution of the present invention is that the pH of the equilibrium solution in the cation exchange chromatography is preferably between 4.5 and 6.0; and the conductivity in the cation exchange chromatography is preferably not higher than 5 ms / cm.
[0030] A further technical solution of the present invention is that the recombinant human albumin sample collected through preliminary purification is human albumin expressed by genetically recombinant microorganisms produced on a large scale.
[0031] The present invention adopting the above technical solution has the following beneficial effects compared with the prior art: the first unique feature of the present invention is that the molar ratio of oleic acid, myristic acid, sodium palmitate, sodium stearate and recombinant human albumin is 0.3:0.3:0.3:0.5:1; that is, the molar ratio of long-chain fatty acids and fatty acid salts: human recombinant albumin is between 0.1 and 3:1; the sequential use of ion exchange chromatography can effectively remove truncated albumin, mismatched or modified albumin in recombinant albumin, which may have side effects on the human body or affect the half-life and efficacy in clinical practice.
[0032] The second unique feature of the present invention is that by adding medium- and long-chain fatty acids and fatty acid salts before refined ion exchange chromatography, the effective fatty acid ligand ratio can be selectively retained through ion exchange, and components with excessive or insufficient ligand ratios due to hydrophobic heterogeneity caused by albumin structural modification or folding errors can be removed through ion exchange, thereby obtaining a high-purity and high-stability human albumin sample. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] In order to further illustrate the present invention, the following is further described with reference to the accompanying drawings:
[0034] FIG1 is a comparison of the charge heterogeneity detection spectra of the sample before Example 1 and after the sequential purification of Example 1 and Example 2; the ordinate of FIG1 is the absorbance (mAU) and the abscissa is the time axis (min);
[0035] Figure 2 shows the accelerated stability experiment, where DLS (dynamic light scattering) was used to measure the particle size distribution of the test sample at 0 hours, 1 month, and 3 months. The ordinate of Figure 2 is the distribution percentage; the abscissa is the molecular diameter (nm).
[0036] Figure 3 shows a long-term stability experiment. DLS (dynamic light scattering) was used to detect the particle size distribution of the test sample at 0 hours, 12 months, 24 months, and 36 months. The vertical axis of Figure 3 is the distribution percentage; the horizontal axis is the molecular diameter (nm). DETAILED DESCRIPTION
[0037] The present invention will be further described below with reference to the accompanying drawings and specific embodiments. It should be understood that the following specific embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0038] The present invention was implemented at fermentation scales of 10 L, 20 L, 3,000 L, and 10,0000 L, and purification scales were implemented at column diameters of 10 cm, 45 cm, and 120 cm, respectively, with good linear scalability. This example includes, but is not limited to, the above scales. The following examples, taken in conjunction with the accompanying drawings, provide a further understanding of the features and advantages of the present invention and do not in any way limit the remainder of the present invention.
[0039] Example 1 Anion Exchange Chromatography
[0040] Recombinant human albumin samples collected during the initial purification phase were exchanged using a Millipore 10kDa membrane evaporation buffer system with 80mM PB pH 7.5. A mixture of oleic acid, myristic acid, sodium palmitate, sodium stearate, and poloxamer was added to the sample collection solution, with the final fatty acid concentrations being a 0.3:0.3:0.3:0.5:1 molar ratio (oleic acid: myristic acid: sodium palmitate: sodium stearate: recombinant human albumin). After loading, a UniGel-DEAE chromatography column (packing height 380mm) was rinsed with purified water until neutral. The column, which had adsorbed the sample, was eluted with 50mM PB pH 6.5 eluent to collect the recombinant human albumin fraction.
[0041] Example 2 Cation exchange chromatography
[0042] Cation exchange chromatography was performed using SP Bestarose FF filler (equivalent to GE SP Sepharose Fast Flow filler) from Boglon (Shanghai) Biotechnology Co., Ltd. The column was equilibrated with a 40 mM HAc-NaOH equilibration system. The recombinant human albumin solution collected in Example 1 was desalted using a Millipore 10 KDa flat membrane and replaced with the equilibration system. Samples were then loaded and chromatographically separated to collect the recombinant human albumin components.
[0043] Example 3: Interchange between cation exchange chromatography and anion exchange chromatography
[0044] In this example, Example 2 was first performed. The recombinant human albumin sample collected after the previous purification step was replaced with the buffer system of Example 2 using a Millipore 10 kDa membrane cassette. A mixture of oleic acid, myristic acid, sodium palmitate, sodium stearate, and poloxamer was added, with the final fatty acid concentrations being in a molar ratio of 0.3:0.3:0.3:0.5:1 (oleic acid: myristic acid: sodium palmitate: sodium stearate: recombinant human albumin). The recombinant human albumin fraction was collected using the same method as in Example 2.
[0045] The collected recombinant human albumin fraction was replaced with the equilibrium solution system of Example 1 using a Millipore 30KDa membrane package, and the column was equilibrated. The same method as in Example 1 was used for purification, sample loading and collection of the recombinant human albumin fraction.
[0046] Upon completion of the above chromatography, 100 KDa and / or 30 KDa and / or 10 KDa membrane packages can be used to retain macromolecular aggregates and remove small molecules, followed by displacement and concentration to a recombinant human albumin stock solution with a concentration greater than 20%. Charge heterogeneity testing was performed on samples before Example 1 and after Examples 1 and 2.
[0047] The charge heterogeneity detection method refers to the ion chromatography method 0513 of the 2020 General Chapter 4 of the Chinese Pharmacopoeia to determine the charge heterogeneity in recombinant human albumin. The test results are as follows (Figure 1);
[0048] Example 4 Accelerated stability test
[0049] This example is the protein solution purified in Example 2. After the final production of the stock solution was completed, a recombinant human albumin injection was prepared; the injection sample was subjected to an accelerated test under the conditions of temperature 25°C ± 2°C and humidity 60% ± 5%, generally observed for 6 months. The test results are (Table 1, Table 2) and the accompanying figure (Figure 1).
[0050] Example 5 Long-term stability experiment
[0051] This example uses the protein solution purified in Example 2. After the stock solution was finally produced, a recombinant human albumin injection was prepared. The injection sample was subjected to long-term stability testing at a temperature of 5°C ± 3°C. The testing was generally conducted every three months in the first year, such as at 0, 3, 6, 9, and 12 months; every six months in the second year, such as at 18 and 24 months; and annually thereafter, such as at 36 months. Test results (Tables 3 and 4) are included, along with the accompanying figure (Figure 3).
[0052] Test results table 1:
[0053] Table 2: DSC test samples at 0 hours and 3 months, T onset 、T m1 、T m2 change.
[0054] Figure 2 shows the particle size distribution of the test samples at 0 hours, 1 month, and 3 months after DLS detection. After the accelerated stability test, the particle size distribution of the samples did not show obvious changes.
[0055] Test results table 3:
[0056] Table 4: T values of the DSC test samples at 0 and 36 months. onset 、T m1 、T m2 change.
[0057] Figure 3 DLS test of the particle size distribution of the test samples at 0, 12 months, 24 months, and 36 months. After the long-term stability experiment, the particle size distribution of the samples did not show obvious changes.
[0058] In summary, the present invention provides a method for removing fragments and mismatched proteins with incorrect structures generated during fermentation and purification of recombinant albumin by adding a certain amount of medium- and long-chain fatty acids and fatty acid salts to a recombinant albumin purification intermediate. The method of the present invention purifies the purified recombinant human albumin solution by cation exchange chromatography, anion exchange chromatography, and other methods.
[0059] 1) Anion exchange chromatography;
[0060] 2) Cation exchange chromatography.
[0061] The cation exchange medium of the present invention is an SP series, or a CM series cation exchange medium, which can be selected from but not limited to the Uni-SP / CM series, UniGel-SP / CM series, NanoGel-SP series, Nano-SP series, Monomix-HC SP series, Monomix-MC SP series, GE's Sepharose series or Boglon Biotechnology Co., Ltd.'s Bestarose series.
[0062] The medium for anion exchange chromatography of the present invention is a DEAE series, or a strong anion Q series. The anion exchange medium may be selected from but is not limited to the Uni-DEAE / Q series, UniGel-DEAE / Q series, NanoGel-Q series, Nano-Q series, Monomix-HC DEAE / Q series, Monomix-MC DEAE / Q series, GE's Sepharose series, or Boglund Biotech Co., Ltd.'s Bestarose series.
[0063] Long-chain fatty acids can be added before anion exchange chromatography or supplemented before cation exchange chromatography.
[0064] The replacement of buffer and concentration between the chromatography steps of the present invention can be carried out using devices and equipment such as hollow fiber membranes and flat membrane packages with separation pore sizes between 1KDa and 30KDa, including but not limited to sequential and cross-use.
[0065] The replacement buffer between the chromatography steps of the present invention can also be carried out using Sephadex G25 or Superdex G75.
[0066] The recombinant albumin preparation with high charge consistency and hydrophobic consistency obtained after the implementation of the present invention can effectively meet the stability requirements of 50 hours at 57°C according to the prescription of the Chinese Pharmacopoeia (2020 edition) or the United States Pharmacopoeia (USP39), and can also be stably stored at 25°C or 30°C for more than 30 days.
[0067] The poloxamer of the present invention is selected from one or more of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407.
[0068] The method of the present invention obtains high-purity recombinant human albumin, which can be applied to the same clinical indications as serum albumin derived from human blood.
[0069] The method of the invention obtains high-purity recombinant human albumin, which can be used in diagnostic reagents, culture media and pharmaceutical excipients.
[0070] The separation medium used in the present invention includes but is not limited to ion exchange media grafted with hydrophilic modified microspheres between 10 μm and 150 μm composed of polyacrylate or polystyrene-divinylbenzene polymer, and can also be Sepharose 6 FF, or any one of the above two polymer base materials or agarose matrix with the length of the grafted side chain.
[0071] The present invention adopts a column bed height of 100 mm to 800 mm, preferably 250 mm to 600 mm.
[0072] The chromatographic conditions of the present invention can be adjusted and changed according to general instruction manuals.
[0073] Other conventional methods can be used to perform dialysis, ultrafiltration, pasteurization and other steps between the chromatography steps described in the present invention without affecting the implementation effect of the present invention.
[0074] After the chromatography of the present invention is finally completed, a 100KDa and / or 30KDa and / or 10KDa membrane package can be used to intercept macromolecular aggregates and remove small molecular substances, and replace and concentrate the recombinant human albumin stock solution with a concentration greater than the preparation concentration.
[0075] The expression host cell described in the present invention is yeast, including Saccharomyces cerevisiae of the genus Saccharomyces, Kluyveromyces, Hansenula and Pichia.
[0076] The basic principles, main features, and advantages of the present invention are shown and described above. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are merely illustrative of the principles of the present invention. Various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention, and such changes and modifications are intended to fall within the scope of the claims.
Claims
1. A method for preparing a high-purity and high-stability protein, characterized in that: The following steps are included: Step A: The recombinant human albumin sample collected through the previous purification process is replaced with an equilibrium solution system containing 80 mM PB pH 7.5 as the buffer using a 10 KDa membrane. The sample collection solution is then added to a mixture comprising a fatty acid mixture and poloxamer; the molar ratio of oleic acid, myristic acid, sodium palmitate, sodium stearate, and recombinant human albumin is 0.3:0.3:0.3:0.5:1; the weight ratio of poloxamer to recombinant albumin is 10-500 μg poloxamer per 1 gram of recombinant albumin; and the poloxamer is used to promote the dissolution of fatty acids. After loading the sample, the anion exchange chromatography column was rinsed with purified water until neutral. The column was packed to a height of 380 mm. The column adsorbed with the sample was eluted with a 50 mM PB pH 6.5 eluent system to collect the recombinant human albumin fraction. Step B: Cation exchange chromatography: The column was equilibrated with a 40 mM HAc-NaOH equilibrium solution system to collect the recombinant human albumin fractions; a 10 KDa flat membrane was used for desalting and replacing the solution with a cation exchange chromatography equilibrium solution system, followed by sample loading and chromatographic separation to collect the recombinant human albumin fractions.
2. The method for preparing a high-purity and high-stability protein according to claim 1, wherein: Step C: The recombinant human albumin sample collected through the previous purification step is replaced with a 30 kDa membrane pack using an equilibrium solution system containing 40 mM HAc-NaOH as the buffer. The cation exchange chromatography column is equilibrated with the equilibrium solution. A mixed solution is added to the sample, wherein the mixed solution is a mixture of a fatty acid mixture and poloxamer; the molar ratio of oleic acid, myristic acid, sodium palmitate, sodium stearate, and recombinant human albumin is 0.3:0.3:0.3:0.5:1; and then the sample is subjected to chromatographic separation to collect the components of the recombinant human albumin. Step D: The recombinant human albumin fraction collected in the above step C is replaced with the equilibrium solution system of step A using a 10KDa membrane package, and the equilibrium solution of step A is used to equilibrate the anion exchange chromatography column. The same method is used for sample loading and purification in step A to collect the recombinant human albumin fraction.
3. A method for preparing a high-purity and high-stability protein according to claim 1 or 2, characterized in that: After step B and / or step D, the following operation is further included: when the above chromatography is finally completed, a 100KDa and / or 30KDa and / or 10KDa membrane package is used to intercept large molecular aggregates and remove small molecular substances, and the membrane is replaced and concentrated to a recombinant human albumin stock solution with a concentration greater than 20%.
4. The method for preparing a high-purity and high-stability protein according to claim 1, wherein: The anion exchange chromatography is purified by forward elution, wherein the pH of the equilibration solution and the eluent are both between 6.0 and 9.5, and the conductivity under the conditions of the anion exchange chromatography of the method of the present invention is not higher than 20 ms / cm; or the anion exchange chromatography is purified by reverse elution, wherein the pH of the equilibration solution is between 4.0 and 6.0, and the equilibrium conductivity under the conditions of the anion exchange chromatography is not higher than 10 ms / cm.
5. The method for preparing a high-purity and high-stability protein according to claim 1, wherein: In the conditions of cation exchange chromatography, the pH of the equilibrium solution is between 4.0 and 6.5; in the conditions of cation exchange chromatography, the conductivity is not higher than 10 ms / cm.
6. The method for preparing a high-purity and high-stability protein according to claim 1, wherein: The recombinant human albumin sample collected after preliminary purification is human albumin expressed by genetically recombinant microorganisms produced on a large scale.
